<DOC>
	<DOCNO>NCT02784080</DOCNO>
	<brief_summary>The aim evaluate impact donor specific HLA alloantibody ( DSA ) all-cause mortality re-transplantation , early allograft dysfunction , acute chronic rejection , fibrosis , vascular , biliary complication . Furthermore , biopsy C4d stain . The hypothesizes donor specific HLA alloantibody facilitate immune mediate damage liver allograft impairs function lead various complication . The investigator prospective blind multicenter cohort study Scandiatransplant organ share organization region . Both preform , persistent , de novo donor specific HLA alloantibody study . Blood sample take immediately prior transplantation , 14 day , 3 month , 1 year transplantation . All liver biopsy perform study period evaluate humoral component blood sample obtain prior liver biopsy investigate presence DSA . Investigations fully blind treatment responsible doctor .</brief_summary>
	<brief_title>Donor Specific HLA Alloantibodies Liver Transplantation</brief_title>
	<detailed_description>The outcome liver transplantation improve drastically time , development stagnate recent year graft failure rate 9-15 % within first year approximately 20-30 % 5 year [ 1 ] . The primary goal improve outcome liver transplantation . The impact donor specific antibody ( DSA ) all-cause mortality re-transplantation , early allograft dysfunction , acute chronic rejection , vascular biliary complication fibrosis investigate . Objectives : 1 . The primary objective investigate DSA pre-formed , persistent , de novo affect survival allograft loss . For patient diagnosed HLA antibody standard Luminex single antigen IgG analysis , Luminex C1q IgG3 single antigen assay perform . 2 . The secondary objective investigate donor specific antibody , pre-formed , persistent , de novo increase risk early allograft dysfunction , acute chronic rejection , fibrosis , de novo autoimmune hepatitis ( pediatric patient ) , vascular biliary complication . All liver biopsy stain C4d DSA analysis undertaken . 3 . Continuous measurement use establish kinetics preformed og de novo DSA liver transplantation . Pediatric patient analyze separately .</detailed_description>
	<mesh_term>Isoantibodies</mesh_term>
	<criteria>Undergo liver transplant study period . Pretransplant serum sample minimum 4 ml ( relevant pediatric patient ) Informed consent give . Withdrawal inform consent . Blinding broken nonprotocoled manner patient exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>HLA alloantibody</keyword>
	<keyword>donor specific antibody</keyword>
	<keyword>Mortality</keyword>
	<keyword>Re-transplantation</keyword>
	<keyword>Rejection</keyword>
	<keyword>Acute rejection</keyword>
	<keyword>Chronic rejection</keyword>
	<keyword>Biliary complication</keyword>
	<keyword>Biliary stricture</keyword>
	<keyword>Arterial thrombosis</keyword>
	<keyword>Arterial stenosis</keyword>
	<keyword>Portal vein thrombosis</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Single antigen bead</keyword>
	<keyword>Cross-match</keyword>
</DOC>